Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

P3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial)

Sanjay Popat,Laura Hughes,Mary O'Brien,Tanya Ahmad,Conrad Lewanski, Ulrike Dernedde,Petra Jankowska,Clive Mulatero,Riyaz Shah,Jonathan Hicks,Tom Geldart,Mathilda Cominos,Gill Gray,James Spicer,Karen Bell,Yenting Ngai,Allan Hackshaw

Journal of Thoracic Oncology（2017）

Cited 3|Views34
Key words
NSCLC,afatinib,mutation,EGFR
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined